Literature DB >> 28260345

[Health economic evaluation reporting guideline and application status].

J Xiao1, J F Sun, Q Q Wang, X Qi, H Y Yao.   

Abstract

Using the guidelines of health economic evaluation reporting is conducive to regulating the contents of this reporting, improving the quality of studies into health economics evaluation. This article summarized the history of the guidelines and specified the instrument used to study " Quality of Health Economic Studies (QHES)" and the checklist about Consolidated Health Economics Evaluation Reporting Standards (CHEERS)-the two specific evaluation contents in this guideline, the article also introduced its present application status of the guideline and its pros and cons. The checklist of CHEERS emphasized the evaluation of this report, while QHES instrument focused on quantitative evaluation on the quality of economic studies. Despite different emphasis, the two guides are actually mutually complemented.

Keywords:  Economics, medical; Guidebooks; Quality assurance, health care

Mesh:

Year:  2017        PMID: 28260345     DOI: 10.3760/cma.j.issn.0253-9624.2017.03.016

Source DB:  PubMed          Journal:  Zhonghua Yu Fang Yi Xue Za Zhi        ISSN: 0253-9624


  8 in total

1.  New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting.

Authors:  Jiangyang Du; Bin Wu
Journal:  Clin Drug Investig       Date:  2020-07       Impact factor: 2.859

2.  Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis.

Authors:  Youwen Zhu; Kun Liu; Dong Ding; Kailing Wang; Xiaoting Liu; Xiao Tan
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

3.  Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.

Authors:  Hongchao Li; Lei Lai; Bin Wu
Journal:  Clin Drug Investig       Date:  2020-02       Impact factor: 2.859

4.  Expanding Antiviral Prophylaxis During Pregnancy to Prevent Perinatal Hepatitis B Virus Infection: A Cost-effectiveness Study.

Authors:  Jiangyang Du; Zhenhua Wang; Bin Wu
Journal:  Open Forum Infect Dis       Date:  2020-04-21       Impact factor: 3.835

5.  Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.

Authors:  Bin Wu; Xiaohua Gu; Qiang Zhang; Feng Xie
Journal:  Oncologist       Date:  2018-09-26

6.  Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.

Authors:  Bin Wu; Qiang Zhang; Jie Sun
Journal:  J Immunother Cancer       Date:  2018-11-20       Impact factor: 13.751

7.  Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.

Authors:  Meng-Meng Teng; Si-Ying Chen; Bo Yang; Yan Wang; Rui-Ying Han; Meng-Na An; Ya-Lin Dong; Hai-Sheng You
Journal:  Cancer Med       Date:  2021-08-12       Impact factor: 4.452

8.  Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration.

Authors:  Rui Chen; Bin Wu
Journal:  Ann Transl Med       Date:  2020-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.